Following a few cases of blood clots, the Netherlands announced on Friday April 2 that they were suspending injections of the AstraZeneca vaccine for those under 60 years of age. These complications have claimed at least one victim, the country’s health authorities said. “The immediate cause of this decision is the notification of cases of thrombosis associated with low platelet counts after vaccinations,” said the public health service GGD.
The move comes after five new cases in the Netherlands affecting women aged 25 to 65, one of whom died, the health ministry said in a statement. “We have to be careful, which is why it is wise to press the pause button as a precaution,” said Health Minister Hugo de Jonge. The Dutch College of Physicians has indicated that these thrombosis problems are similar to those detected in other European countries. “This is of course worrying, because a relatively young person died,” said Ton de Boer, the president of the Order, in a statement.
A similar measure in Germany
The suspension is expected to last until April 7, when the European Medicines Agency (EMA) is expected to give further advice on the matter, he added. Germany took a similar decision earlier this week, the Dutch health ministry said. About 10,000 vaccinations that were planned for next week for members of the Dutch health services under the age of 60 have been postponed, the GGD said. The EMA said on Wednesday that it believes the AstraZeneca vaccine is safe and that experts have not found any specific risk factors such as age, gender or medical history.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
